{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:04:23Z","timestamp":1787313863725,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303966"],"award-info":[{"award-number":["82303966"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01470-6","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:15:47Z","timestamp":1777119347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CD74+tumour-Associated Macrophages Promote Immune Escape through Autonomous PD-L1 Eexpression in Gastric Cancer"],"prefix":"10.1007","volume":"57","author":[{"given":"Tianwei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueda","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dansong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"1470_CR1","doi-asserted-by":"crossref","unstructured":"Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20(5):338\u201349.","DOI":"10.1038\/s41571-023-00747-0"},{"issue":"5","key":"1470_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584\u201390.","journal-title":"Chin Med J (Engl)"},{"issue":"31","key":"1470_CR3","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991\u20137.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1470_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S2468-1253(19)30083-4","volume":"4","author":"Y Yamada","year":"2019","unstructured":"Yamada Y, Boku N, Mizusawa J, et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(7):501\u201310.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"1470_CR5","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/jamaoncol.2021.0848","volume":"7","author":"PS Hall","year":"2021","unstructured":"Hall PS, Swinson D, Cairns DA, et al. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7(6):869\u201377.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1470_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215\u201321.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1470_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s10120-015-0457-4","volume":"19","author":"J Wang","year":"2016","unstructured":"Wang J, Xu R, Li J, et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer. 2016;19(1):234\u201344.","journal-title":"Gastric Cancer"},{"issue":"11","key":"1470_CR8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Yanez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395.","journal-title":"Lancet Oncol"},{"issue":"suppl 5","key":"1470_CR9","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","volume":"27","author":"EC Smyth","year":"2016","unstructured":"Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38\u201349.","journal-title":"Ann Oncol"},{"issue":"1","key":"1470_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-020-01042-y","volume":"24","author":"Japanese Gastric Cancer A","year":"2021","unstructured":"Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1\u201321.","journal-title":"Gastric Cancer"},{"issue":"10294","key":"1470_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"issue":"6","key":"1470_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","volume":"19","author":"MJ Pittet","year":"2022","unstructured":"Pittet MJ, Michielin O, Migliorini D. Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022;19(6):402\u201321.","journal-title":"Nat Rev Clin Oncol"},{"key":"1470_CR13","doi-asserted-by":"publisher","first-page":"874589","DOI":"10.3389\/fimmu.2022.874589","volume":"13","author":"Y Pu","year":"2022","unstructured":"Pu Y, Ji Q. Tumor-Associated Macrophages Regulate PD-1\/PD-L1 Immunosuppression. Front Immunol. 2022;13:874589.","journal-title":"Front Immunol"},{"issue":"12","key":"1470_CR14","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41423-024-01232-z","volume":"21","author":"J Kzhyshkowska","year":"2024","unstructured":"Kzhyshkowska J, Shen J, Larionova I. Targeting of TAMs: can we be more clever than cancer cells? Cell Mol Immunol. 2024;21(12):1376\u2013409.","journal-title":"Cell Mol Immunol"},{"key":"1470_CR15","doi-asserted-by":"crossref","unstructured":"Wang Z, Wang B, Feng Y et al. Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer. J Immunother Cancer. 2024; 12(8):e009024.","DOI":"10.1136\/jitc-2024-009024"},{"issue":"2","key":"1470_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00262-023-03604-2","volume":"73","author":"J Wang","year":"2024","unstructured":"Wang J, Li X, Xiao G, et al. CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1\/CTLA-4 bispecific antibody in patients with solid tumors. Cancer Immunol Immunother. 2024;73(2):36.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1470_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10565-024-09982-2","volume":"41","author":"Y Sun","year":"2025","unstructured":"Sun Y, Yang B, Wen T, et al. ANXA10 sensitizes microsatellite instability-high colorectal cancer to anti-PD-1 immunotherapy via assembly of HLA-DR dimers by regulating CD74. Cell Biol Toxicol. 2025;41(1):25.","journal-title":"Cell Biol Toxicol"},{"issue":"8","key":"1470_CR18","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/bjs.10546","volume":"104","author":"C Lin","year":"2017","unstructured":"Lin C, Liu H, Zhang H, et al. Tryptase expression as a prognostic marker in patients with resected gastric cancer. Brit J Surg. 2017;104(8):1037\u201344.","journal-title":"Brit J Surg"},{"key":"1470_CR19","doi-asserted-by":"crossref","unstructured":"Xue A, Cao Y, Yu K et al. Disrupting of tissue-resident FOLR2 + tumour-associated macrophages-derived interleukin-10 improves anti-PD-1 efficacy in gastric cancer. Int J Surg. 2025;112(3):6270\u201383.","DOI":"10.1097\/JS9.0000000000004105"},{"issue":"5","key":"1470_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","volume":"23","author":"JA Ajani","year":"2025","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(5):169\u201391.","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"1470_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discovery. 2022;21(11):799\u2013820.","journal-title":"Nat Rev Drug Discovery"},{"issue":"4","key":"1470_CR22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","volume":"23","author":"L Cassetta","year":"2023","unstructured":"Cassetta L, Pollard JW. A timeline of tumour-associated macrophage biology. Nat Rev Cancer. 2023;23(4):238\u201357.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1470_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41698-024-00660-4","volume":"8","author":"C Wei","year":"2024","unstructured":"Wei C, Ma Y, Wang M, et al. Tumor-associated macrophage clusters linked to immunotherapy in a pan-cancer census. NPJ Precis Oncol. 2024;8(1):176.","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"1470_CR24","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s10120-014-0422-7","volume":"18","author":"H Zhang","year":"2015","unstructured":"Zhang H, Wang X, Shen Z, Xu J, Qin J, Sun Y. Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection. Gastric Cancer. 2015;18(4):740\u201350.","journal-title":"Gastric Cancer"},{"issue":"15","key":"1470_CR25","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/0008-5472.CAN-11-3990","volume":"72","author":"HJ Jun","year":"2012","unstructured":"Jun HJ, Johnson H, Bronson RT, de Feraudy S, White F, Charest A. The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. Cancer Res. 2012;72(15):3764\u201374.","journal-title":"Cancer Res"},{"issue":"11","key":"1470_CR26","doi-asserted-by":"publisher","first-page":"e3002905","DOI":"10.1371\/journal.pbio.3002905","volume":"22","author":"B Pellegrino","year":"2024","unstructured":"Pellegrino B, David K, Rabani S, et al. CD74 promotes the formation of an immunosuppressive tumor microenvironment in triple-negative breast cancer in mice by inducing the expansion of tolerogenic dendritic cells and regulatory B cells. PLoS Biol. 2024;22(11):e3002905.","journal-title":"PLoS Biol"},{"issue":"7","key":"1470_CR27","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1111\/cas.14038","volume":"110","author":"M Imaoka","year":"2019","unstructured":"Imaoka M, Tanese K, Masugi Y, Hayashi M, Sakamoto M. Macrophage migration inhibitory factor-CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells. Cancer Sci. 2019;110(7):2273\u201383.","journal-title":"Cancer Sci"},{"issue":"9742","key":"1470_CR28","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"11","key":"1470_CR29","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","volume":"23","author":"ZA Wainberg","year":"2022","unstructured":"Wainberg ZA, Enzinger PC, Kang YK, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022;23(11):1430\u201340.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1470_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1200\/JCO.24.00410","volume":"43","author":"SJ Klempner","year":"2025","unstructured":"Klempner SJ, Sonbol MB, Wainberg ZA, et al. DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish. J Clin Oncol. 2025;43(3):339\u201349.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1470_CR31","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/annonc\/mdx047","volume":"28","author":"C Boger","year":"2017","unstructured":"Boger C, Kruger S, Behrens HM, et al. Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations. Ann Oncol. 2017;28(5):1005\u201314.","journal-title":"Ann Oncol"},{"issue":"4","key":"1470_CR32","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.21873\/anticanres.13328","volume":"39","author":"AN Seo","year":"2019","unstructured":"Seo AN, Kang BW, Bae HI, et al. Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer. Anticancer Res. 2019;39(4):2145\u201354.","journal-title":"Anticancer Res"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01470-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01470-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01470-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:15:49Z","timestamp":1777119349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01470-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01470-6","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"101"}}